Medindia

X

Indian Immunologicals Limited Sets Up a New Rs. 250 Crore Facility in Hyderabad

by Dr. Trupti Shirole on  October 27, 2015 at 4:24 PM Corporate News   - G J E 4
The Indian Immunologicals Limited (IIL) is a leading biologicals company in the country. It has set up a new facility with an investment of Rs. 250 crore near Hyderabad and is set to become India's largest producer of animal health formulations.
 Indian Immunologicals Limited Sets Up a New Rs. 250 Crore Facility in Hyderabad
Indian Immunologicals Limited Sets Up a New Rs. 250 Crore Facility in Hyderabad
Advertisement

The state-of-the-art facility at Karkapatla in Ranga Reddy district has commenced operations, and will manufacture vaccines against infectious diseases of humans and animal health formulations catering to domestic as well as international markets.

‘The state-of-the-art facility at Karkapatla in Ranga Reddy district has commenced operations, and will manufacture vaccines against infectious diseases of humans and animal health formulations catering to domestic as well as international markets. The IIL has developed this facility considering the growing demand for the next 10 years for human vaccines and animal health formulations.’
Advertisement
Spread over 47 acres at Karkapatla is IIL's second manufacturing unit in Hyderabad and will significantly expand the company's manufacturing capabilities. The IIL has developed this facility considering the growing demand for the next 10 years for human vaccines and animal health formulations.

The first phase of human vaccine facility at IIL has the capacity to produce eight million doses of human rabies vaccine, while the animal health formulation facility is equipped to produce an estimated capacity of 300 million tablets, 100 million bolus, and 20 million vials of injectables.

With this new addition, IIL has five manufacturing facilities at various locations. Its anti rabies production unit is located at Ooty, cattle feed unit at Rajkot, biological unit at Gachibowli, Hyderabad and serum manufacturing unit is in New Zealand.

Deputy managing director K. Anand Kumar said, "The facility will strengthen IIL's position in the industry and will immensely increase our manufacturing capabilities. We are expecting this plant to play a key role in manufacturing top quality vaccines with the most recent German technology."

Source: IANS
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All